# Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

> **NCT01093911** · PHASE1 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 44 (actual)

## Conditions studied

- Immune System Diseases
- Autoimmune Diseases
- Lupus Erythematosus, Systemic
- Skin and Connective Tissue Diseases
- Connective Tissue Disease

## Interventions

- **BIOLOGICAL:** CDP7657
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01093911
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093911, "Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01093911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*